Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
about
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatmentImmunotherapy in non-small cell lung cancer: the clinical impact of immune response and targetingImmunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsMechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancerNew targeted treatments for non-small-cell lung cancer - role of nivolumabPD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?A Perspective of Immunotherapy for Prostate CancerImmunotherapy for head and neck cancer: latest developments and clinical potentialCurrent status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyEmerging molecular classifications and therapeutic implications for gastric cancerProfile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancerSpotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so farIs metastatic pancreatic cancer an untargetable malignancy?PD-1/PD-L1 blockades in non-small-cell lung cancer therapyAdvanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approachesPD-1/PD-L1 blockade in cancer treatment: perspectives and issuesResults of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancerProgrammed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta roleNovel Drugs and Combination Therapies for the Treatment of Metastatic MelanomaImportance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodiesImmune checkpoint inhibitors in clinical practice: update on management of immune-related toxicitiesTreatment of advanced squamous cell carcinoma of the lung: a reviewCTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their InhibitionAdvances in immunotherapy for treatment of lung cancerThe anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsTargeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enoughPredictive biomarkers in precision medicine and drug development against lung cancerUpdate in Lung Cancer 2014Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.The PD1:PD-L1/2 Pathway from Discovery to Clinical ImplementationPD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune ResponsesThe Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung CancerTrends and advances in tumor immunology and lung cancer immunotherapyThe promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1Targeting immune checkpoints in malignant gliomaUpdate on clinical research and state of the art management of patients with advanced sarcomas and GISTFocus on Nivolumab in NSCLC
P2860
Q26738359-DA2C5924-C0EA-49D3-B58C-25A7E14257C1Q26738673-ED379E4C-F1DD-4AEA-80C6-99CD604D3B6CQ26738810-5DB8F41F-6FF6-4BDC-B8E2-C98E4DE2EF4AQ26740288-FC2FB935-0C4C-4166-96AC-E4AFBADC3FA9Q26740988-46D81103-DF87-4F59-8B30-5D43D7D409EDQ26741101-0F54E435-0EB7-4295-9E33-DF76E681AB32Q26741277-0C634336-5DAE-44A6-9131-AD808780E798Q26745428-E0B56B51-18C6-4D07-8131-4EDA62295E75Q26745516-198FAEE7-32AB-4CD7-8490-5EAE899A2800Q26745525-F27D3DE2-588D-4FD2-B827-FF13CB8DB4E3Q26745590-10AAC24D-BE84-446E-8E5D-EF1D589C679BQ26745776-11FBFBB4-55EB-4BA6-8CE1-C9366FBAE2A3Q26753849-DE5AFD0D-135C-43B8-99D7-7DD2AA5C15F1Q26765024-C566B799-4144-41A1-BB9C-665C8EEF7449Q26767046-827139B6-2A71-45F2-8EBB-15A0B52C90DFQ26768641-7B478855-694D-4165-B180-3C4B82E57658Q26769713-C772875F-18B5-49A0-A74E-6259FEFEFA98Q26769734-CEB022A0-B415-49CB-A6B8-4AD2D5763933Q26772015-79EF4D91-2A4B-4A2B-8F21-2CDD1357F3F4Q26775034-57B54D8C-2C6D-4052-969E-DD48A3553635Q26775383-47C63D32-7B7A-4409-89EA-87CD78218D34Q26775392-28CDC191-6852-4839-8FAA-4979183D554EQ26777563-6499AEC0-7D14-4518-A132-82B553F6E031Q26778790-26D77B54-4E2D-4F67-8C22-41B347A1D9D8Q26797478-132E095E-D81B-4BC9-86AF-3E96E9D2C0D3Q26799467-6A61339D-71FD-45DC-BA66-A39360DE291FQ26824536-E4E4B26A-13A3-414B-8D9E-B64D80D141D9Q27027385-B752CB86-FE17-47EB-A25E-AE17D53EE1D6Q27853176-F8B9167D-38B2-4543-B679-BF82C4AEC652Q27853331-48416178-B305-4659-AE9B-75B21BD65A50Q27853339-82C6154A-49CE-4D3D-9E29-253FC25C0F55Q27853353-80DCC4B2-8774-4C42-AC99-A079E2818C32Q28066941-2143280F-0E01-4D89-8508-40BC96B82A14Q28067141-9F65D328-33B8-42A4-BD81-2217C896F0C8Q28067196-3338B455-28C9-4281-9610-12EFBFF2569DQ28067674-4EE8FF87-2FDC-40DC-B9F5-32D27BD6D294Q28069924-9D58F400-5537-4E17-867E-B6B6F8F88512Q28072012-17914948-44A3-43C7-B1CB-55CF167BE0E4Q28073290-07A3F1AF-E5A7-411A-8D7F-B3B2968B7312Q28073759-2440E007-F174-466E-A619-6AC49D8B954A
P2860
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Activity and safety of nivolum ...... : a phase 2, single-arm trial.
@en
type
label
Activity and safety of nivolum ...... : a phase 2, single-arm trial.
@en
prefLabel
Activity and safety of nivolum ...... : a phase 2, single-arm trial.
@en
P2093
P2860
P50
P1433
P1476
Activity and safety of nivolum ...... : a phase 2, single-arm trial.
@en
P2093
Afshin Dowlati
Ariel Lopez-Chavez
Benjamin P Levy
Bertrand Mennecier
Brian J Lestini
Christian Grohe
Christine Baudelet
Christopher T Harbison
David Planchard
Editta Baldini
P2860
P304
P356
10.1016/S1470-2045(15)70054-9
P577
2015-02-20T00:00:00Z